Thu, Nov 27, 2014, 8:52 AM EST - U.S. Markets closed for Thanksgiving Day

Recent

% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • insidetrack22 insidetrack22 Dec 5, 2012 1:36 PM Flag

    Here is what is going to happen to IMGN

    As soon as T-DM1 gets approved by the FDA on Feb 26th, Roche will make a bid to takeover IMGN. This makes sense because (1) By owning IMGN, Roche can protect the Herceptin's $1BB market by owning the rights to TAP technology (2) IMGN is sitting on $200MM cash which Roche can use IMGN's own cash to finance the takeover (3) Roche by acquiring IMGN now has a pipeline rich of future TAP based products (4) Roche has the sales/marketing muscles to bury SGEN. IMGN's current partners may also make a bid for IMGN. The bottom line is: As we approach Feb 26th approval date, IMGN price will drift up, once Tap technology is validated with a FDA approval of T-DM1, IMGN worth will sky-rocket with many bidders ready to make an offer on acquiring IMGN. IMGN's management and BOD knows what is coming so they are preparing an exit strategy now by enriching themselves now (with options) before the party is over. In the long run, getting rid of IMGN inept management is a good thing for investors.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
IMGN
10.35+0.51(+5.18%)Nov 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.